Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire

Pediatric Infectious Disease Journal

Volumn 24, Issue 12, 2005, Pages 1072-1076

  Chaix, Marie Laure ^a   Rouet, François ^b   Kouakoussui, Kouakou Alain ^c   Laguide, Rockiath ^c   Fassinou, Patricia ^d   Montcho, Crepin ^b   Blanche, Stéphane ^e   Rouzioux, Christine ^a   Msellati, Philippe ^c,f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^c Programme Enfant Yopougon/PACCI   (Côte d’Ivoire)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

C te d'Ivoire; Highly active antiretroviral therapy; Human immunodeficiency virus type 1 infected children; Resistant virus

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN;

EID: 29444451897     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000190413.88671.92     Document Type: Article

References (27)

1. Spira R, Lepage P, Msellati P, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda: Mother-to-Child HIV-1 Transmission Study Group. Pediatrics. 1999;104:e56.
2. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000;106:e77.
3. Dabis F, Elenga N, Meda N, et al. 18-month mortality and perinatal exposure to zidovudine in West Africa. AIDS. 2001;15:771-779.
4. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905-1913.
5. Teglas JP, Mayaux MJ, Blanche S. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA. 2000;284:2871-2872.
6. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102.
7. Eshleman SH, Krogstad P, Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis. 2001;183:1732-1738.
8. Faye A, Bertone C, Teglas JP, et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J. 2002;21:518-525.
9. Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS. 2004;18:237-245.
10. Mullen J, Leech S, O'Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002;68:299-304.
11. Centers for Disease Control and Prevention. 1994 revised classification systems for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43:1-19.
12. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-128.
13. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
14. Felsenstein J. PHYLIP, Phylogeny Inference Package, version 3. 6(α). Seattle, WA: Department of Genetics, University of Washington, 2001.
15. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial: PACTG 377. AIDS Res Hum Retroviruses. 2000;16:1113-1121.
16. Delaugerre C, Teglas JP, Treluyer JM, et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ ritonavir. J Acquir Immune Defic Syndr. 2004;37:1269-1275.
17. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216-224.
18. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Antivir Ther. 2004;9:297-299.
19. Schwarzwald H, Anabwani G, Bowman D, et al. Botswana/Baylor antiretroviral assessment trial experience with antiretroviral medications in resource constrained setting. In: 11th Conference on Retroviruses and Opportunistic Infections. 2004, San Francisco, CA. Abstract 585.
20. Neal LJ, Yoganathan K, Roux P. HIV treatment in South African children. Lancet. 2004;364:26.
21. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29:165-168.
22. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2001;26:501-506.
23. Harries AD, Nyangulu DS, Hargreaves NJ, et al. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet. 2001;358:410-414.
24. Adje-Toure C, Fassinou P, Borget MY, et al. Genotypic HIV-1 drug resistant strains among children receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. In: XV International AIDS Conference. Bangkok, Thailand 2004. Abstract B10612.
25. Vergne L, Kane CT, Laurent C, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS. 2003;17(suppl 3):S31-S38.
26. Clotet B, Ruiz L, Martinez-Picado J, et al. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials. 2002;3:316-323.
27. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother. 2004;48:2159-2165.